CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 28, 2007--POZEN Inc.
(NASDAQ: POZN) announced today that Marshall E. Reese, Ph.D., the
company's executive vice president, product development, will
participate in the "Current Treatments for Pain Management" panel at
the Oppenheimer "Positioning Investors For The Next Wave In Pain
Management" Conference on Tuesday, March 6, 2007 at 8:30 a.m. (ET) at
the Flatotel in New York City.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT Technology(TM),
and naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration; and with AstraZeneca for proprietary fixed
dose combinations of naproxen with the proton pump inhibitor
esomeprazole magnesium in a single tablet for conditions such as
osteoarthritis and rheumatoid arthritis in patients who are at risk
for developing NSAID-associated gastric ulcers. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN".
For detailed company information, including copies of this and other
press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.
Chief Financial Officer
Director, Investor Relations
SOURCE: POZEN Inc.